Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization: Comparative studies in a murine model

Experimental Hematology

Volumn 27, Issue 3, 1999, Pages 553-560

  Verma, Udit N ^a   Van Den Blink, Bernt ^a   Pillai, Ravindran ^a   Chawla, Jasvinder ^a   Mazumder, Amitabha ^a   Herscowitz, Herbert B ^b   Meehan, Kenneth R ^a  

^a Division of Hematology and Oncology   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Animal model; Cyclophosphamide; Paclitaxel; Priming chemotherapy; Stem cells

Indexed keywords

CYCLOPHOSPHAMIDE; PACLITAXEL;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; COLONY FORMING UNIT C; DRUG POTENCY; FEMALE; GROWTH REGULATION; LYMPHOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL;

ANIMALS; CONCANAVALIN A; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; INTERLEUKIN-2; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PACLITAXEL; SPLEEN; TUMOR CELLS, CULTURED;

ANIMALIA; BOS GRUNNIENS; MURINAE;

EID: 0033052289     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(98)00044-7     Document Type: Article

References (19)

1. Kotasek D., Sage R.E., Dale B.M.et al. Dose intensive therapy with autologous blood stem cell transplantation in breast cancer. Aust N Z J Med. 24:1994;288.
2. Ayash L.J. High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer. Cancer. 74:1994;532.
3. + cells. Blood. 84:1994;2930.
4. + hematopoietic stem cells in the peripheral blood of high dose cyclophosphamide-treated patients. enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor Blood. 74:1989;1905.
5. Arbuck S.G. Paclitaxel. current developmental approaches of the National Cancer Institute Semin Oncol. 22:1995;55.
6. Markman M., Hakes T., Barakat R.et al. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute treatment referral center protocol 9103. paclitaxel in refractory ovarian cancer J Clin Oncol. 14:1996;796.
7. O'Shaughnessy J.A., Cowan K.H. Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat. 33:1995;27.
8. + cells for stem cell transplantation. Blood. 86:1995;405(abstr).
9. Demirer T., Rowley S., Buckner C.D.et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol. 13:1995;1714.
10. Fennelly D., Schneider J., Spriggs D.et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol. 13:1995;1160.
11. Meehan K.R., Rajagopal C., Verma U.N.et al. Interleukin-2 activated hematopoietic stem cell transplantation for breast cancer. investigation of dose level with clinical correlates Bone Marrow Transplant. 20:1997;643.
12. Verma U.N., Yankelevich B., Hodgson J.et al. Effect of the in vivo priming regimen for peripheral blood stem cells (PBSC) mobilization on in vitro generation of cytotoxic effectors by IL-2 activation of PBSC in a murine model. Bone Marrow Transplant. 19:1997;265.
13. Neben S., Marcus K., Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood. 81:1993;1960.
14. Innocenti F., Danesi R., Di Paolo A.et al. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos. 23:1995;713.
15. Milas L., Hunter N.R., Kurdoglu B.et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol. 35:1995;297.
16. Charak B.S., Agah R., Gray D., Mazumder A. Interaction of various cytokines with interleukin-2 in the generation of killer cells from human bone marrow. application in purging of leukemia Leuk Res. 15:1991;801.
17. Kessinger A., Armitage P., Bierman P.et al. Clinical outcome of peripheral blood stem cell support. Med Oncol. 11:1994;43.
18. To L.B., Roberts M.M., Haylock D.N.et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogenic bone marrow transplants. Bone Marrow Transplant. 9:1992;277.
19. Meehan K.R., Hassan R., Wu A.G., Chawla J., Herscowitz H.B. Enhancement of tumor cell-directed cytotoxicity and purging by activation of human peripheral blood stem cells with combination cytokines. Blood. 90:1997;316a(abstr).